174 related articles for article (PubMed ID: 33011288)
1. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
2. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C
J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Olsen JB; Cao XJ; Han B; Chen LH; Horvath A; Richardson TI; Campbell RM; Garcia BA; Nguyen H
Mol Cell Proteomics; 2016 Mar; 15(3):892-905. PubMed ID: 26750096
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Cowen SD; Russell D; Dakin LA; Chen H; Larsen NA; Godin R; Throner S; Zheng X; Molina A; Wu J; Cheung T; Howard T; Garcia-Arenas R; Keen N; Pendleton CS; Pietenpol JA; Ferguson AD
J Med Chem; 2016 Dec; 59(24):11079-11097. PubMed ID: 28002961
[TBL] [Abstract][Full Text] [Related]
7. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Ju Han H; Sub Byun W; Ho Lee G; Kyung Kim W; Jang K; Yang S; Yang J; Woo Ha M; Hong S; Lee J; Shin J; Bong Oh K; Kook Lee S; Park HG
Bioorg Med Chem; 2021 Apr; 35():116072. PubMed ID: 33636429
[TBL] [Abstract][Full Text] [Related]
9. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
10. Structure-Activity Relationship Studies on (R)-PFI-2 Analogues as Inhibitors of Histone Lysine Methyltransferase SETD7.
Lenstra DC; Damen E; Leenders RGG; Blaauw RH; Rutjes FPJT; Wegert A; Mecinović J
ChemMedChem; 2018 Jul; 13(14):1405-1413. PubMed ID: 29869845
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
12. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
13. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
[TBL] [Abstract][Full Text] [Related]
14. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Reynoird N; Mazur PK; Stellfeld T; Flores NM; Lofgren SM; Carlson SM; Brambilla E; Hainaut P; Kaznowska EB; Arrowsmith CH; Khatri P; Stresemann C; Gozani O; Sage J
Genes Dev; 2016 Apr; 30(7):772-85. PubMed ID: 26988419
[TBL] [Abstract][Full Text] [Related]
15. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T
Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterizations of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular Fingerprint-Based Similarity Search.
Ding H; Lu WC; Hu JC; Liu YC; Zhang CH; Lian FL; Zhang NX; Meng FW; Luo C; Chen KX
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498708
[TBL] [Abstract][Full Text] [Related]
18. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
Remiszewski SW; Sambucetti LC; Atadja P; Bair KW; Cornell WD; Green MA; Howell KL; Jung M; Kwon P; Trogani N; Walker H
J Med Chem; 2002 Feb; 45(4):753-7. PubMed ID: 11831887
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of substrate methylation and inhibition of SMYD2.
Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
